A particular anti-arrhythmia drug provides a targeted treatment for certain forms of atrial fibrillation.

Variation in the gene for the beta-1 adrenergic receptor increases the risk that a patient will have an abnormal heart rhythm after cardiac surgery.

A genetic variant that increases risk for atrial fibrillation also impacts the response to a common therapy for the heart rhythm disorder.

A team led by Vanderbilt University investigators has discovered two new genes — both coding for the signaling protein calmodulin — associated with severe early-onset disorders of heart rhythm.